Cellular membrane permeability of anthracyclines does not correlate with their delivery in a tissue-isolated tumor

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4458-4463

  Heijn, Marc ^a,b   Roberge, Sylvie ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BOVINE SERUM ALBUMIN; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN;

ANIMAL MODEL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG PENETRATION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL MEMBRANE PERMEABILITY; FEMALE; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; SERUM ALBUMIN, BOVINE; TUMOR CELLS, CULTURED;

EID: 0033200067     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Weiss, R. B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol., 19: 670-686, 1992.
2. Mülder, H. S., Dekker, H., Pinedo, H. M., and Lankelma, J. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several antracyclines with varying lipophilicity. Biochem. Pharmacol., 50: 967-974, 1995.
3. Mankhetkorn, S., Dubru, F., Hesschenbrouck, J., Fiallo, M., and Garnier-Suillerot, A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluorcidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol. Pharmacol., 49: 532-539, 1996.
4. Praet, M., Stryckmans, P., and Ruysschaert, J. Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and mullidrug-resistant K562 cells. Biochem. Pharmacol., 51: 1341-1348, 1996.
5. Casazza, A. M. Experimental evaluation of anthracycline analogs. Cancer Treat. Reports, 63: 835-844, 1979.
6. Maniez-Devos, D. M., Baurain, R., Lesne, M., and Trouet, A. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation. J. Pharmacol., 17: 1-13, 1986.
7. Paul, C., Liliemark, J., Tidefelt, U., Gahrton, G., and Peterson, C. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther. Drug Monit., 11: 140-148, 1989.
8. Speth, P. A., Minderman, H., and Haanen, C. Idarubicin versus daunorubicin: preclinical and clinical pharmacokinetic studies. Semin. Oncol., 16 (Suppl. 2): 2-9, 1989.
9. Schott, B., and Robert, J. Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem. Pharmacol., 38: 167-172, 1989.
10. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res., 47: 3039-3051, 1987.
11. Jain, R. K. Determinants of tumor blood flow: a review. Cancer Res., 48: 2641-2658, 1988.
12. Gullino, P. M., and Grantham, F. H. Studies on the exchange of fluids between host and tumor. I. A method for growing "tissue-isolated" tumors in laboratory animals. J. Natl. Cancer Inst., 27: 679-693, 1961.
13. Ohkouchi, K., Imoto, H., Takakura, Y., Hashida, M., and Sezaki, H. Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. Cancer Res., 50: 1640-1644, 1990.
14. Jain, R. K., Wei, J., and Gullino, P. M. Pharmacokinetics of methotrexate in solid tumors. J. Pharmacokinet. Biopharm., 7: 181-194, 1979.
15. Kristjansen, P. E., Roberge, S., Lee, I., and Jain, R. K. Tissue-isolated human tumor xenografts in athymic nude mice. Microvasc. Res., 48: 389-402, 1994.
16. Kristjansen, P. E. G., Brown, T. J., Shipley, L. A., and Jain, R. K. Intratumor Pharmacokinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer. Clin. Cancer Res., 2: 359-367, 1996.
17. Sevick, E. M., and Jain, R. K. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res., 49: 3506-3512, 1989.
18. Eskey, C. J., Wolmark, N., McDowell, C. L., Domach, M. M., and Jain, R. K. Residence time distributions of various tracers in tumors: implications for drug delivery and blood flow measurement. J. Natl. Cancer Inst., 86: 293-299, 1994.
19. Netti, P. A., Roberge, S., Boucher, Y., Baxter, L. T., and Jain, R. K. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc. Res., 52: 27-46, 1996.
20. Demant, E. J. F., and Friche, E. Equilibrium binding of anthracycline cytostatics to serum albumin and small unilamellar phospholipid vesicles as measured by gel filtration. Biochem. Pharmacol., 55: 27-32, 1998.
21. Less, J. R., Skalak, T. C., Sevick, E. M., and Jain, R. K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res., 51: 265-273, 1991.
22. Milici, A. J., L'Hernault, N., and Palade, G. E. Surface densities of diaphragmed fenestrae and transendothelial channels in different murine capillary beds. Circ. Res., 56: 709-717, 1985.
23. Sung, C., Youle, R. J., and Dedrick, R. L. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding. Cancer Res., 50: 7382-7392, 1990.
24. Cirilli, M., Bachechi, F., Ughetto, G., Colonna, F. P., and Capobianco, M. L. Interactions between morpholinyl anthracyclines and DNA; the crystal structure of a morpholino doxorubicin bound to d(CGTACG). J. Mol. Biol., 230: 878-889, 1992.
25. Hirata, A., Baluk, P., Fujiwara, T., and McDonald, D. M. Location of focal silver staining at endothelial gaps in inflamed venules examined by scanning electron microscopy. Am. J. Physiol., 269: L403-L418, 1995.
26. Hilmas, D. E., and Gillette, E. L. Morphometric analyses of the microvasculature of tumors during growth and after X-irradiation. Cancer (Phila.), 33: 103-110, 1974.
27. Durand, R. E., and LePard, N. E. Contribution of transient blood flow to tumor hypoxia in mice. Acta Oncol., 34: 317-323, 1995.
28. 2H-Nuclear magnetic resonance imaging of tumor blood flow: spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. Cancer Res., 52: 6010-6019, 1992.
29. El-Kareh, A. W., and Secomb, T. W. Theoretical models for drug delivery to solid tumors. Crit. Rev. Biomed. Engin., 25: 503-571, 1997.
30. Ozols, R. F., Locker, G. Y., Doroshow, J. H., Grotzinger, K. R., Myers, C. E., and Young, R. C. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res., 39: 3209-3214, 1979.
31. St Croix, B., and Kerbel, R. S. Cell adhesion and drug resistance in cancer Curr. Opin. Oncol., 9: 549-556, 1997.